Alamandine attenuates long‑term hypertension‑induced cardiac fibrosis independent of blood pressure

Wang,Lan; Liu,Chi; Chen,Xiru; Li,Peng

doi:10.3892/mmr.2019.10167

Alamandine attenuates long‑term hypertension‑induced cardiac fibrosis independent of blood pressure

Authors:
- Lan Wang
- Chi Liu
- Xiru Chen
- Peng Li
View Affiliations

Affiliations: Department of Cardiology, Jiangsu Province Geriatric Hospital, Nanjing Medical University, Nanjing, Jiangsu 210024, P.R. China, Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: April 15, 2019 https://doi.org/10.3892/mmr.2019.10167
Pages: 4553-4560
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiac fibrosis secondary to long‑term hypertension is known to promote cardiac dysfunction; however, few therapeutic agents are available for the treatment of this condition in clinical practice. The heptapeptide alamandine (Ala) has recently been identified as a component of the renin‑angiotensin system (RAS), which exerts a protective effect against cardiac hypertrophy; however, it is unknown whether Ala may also be useful for the treatment of cardiac fibrosis. In the present study, the potential therapeutic effects of Ala on long‑term hypertension‑induced cardiac fibrosis were investigated in an aged, spontaneous hypertensive rat model. Weekly blood pressure (BP) measurements revealed that daily Ala treatment significantly decreased the systolic, diastolic and mean arterial BP compared with the control. Of note, the observed reduction in BP in Ala‑treated animals markedly differed to that observed in rats treated with hydralazine (Hyd). Echocardiography further demonstrated that Ala treatment decreased the ratio of left ventricle mass to body weight, and alleviated structural and functional parameters associated with cardiac fibrosis, including left ventricular volume, ejection fraction and fractional shortening compared with the control and Hyd‑treated groups. Furthermore, Ala deceased the density of cardiac fibrosis, as assessed by Masson and Sirius red staining; reduced expression of fibrotic proteins, including connective tissue growth factor, collagen I (COL1A1) and matrix metalloproteinase 9, was also observed. In addition, Ala treatment further decreased the expression of angiotensin II‑induced fibrotic markers at the mRNA and protein levels in cultured cardiac fibroblasts; Ala‑mediated inhibition of COL1A1 expression and Akt phosphorylation was inhibited via the Mas‑related G protein receptor antagonist, PD123319. Collectively, the findings of the present study suggest that Ala is an effective anti‑hypertensive peptide that can attenuate cardiac dysfunction and fibrosis induced by chronic hypertension, independent of BP.

View Figures

View References

1	Fujiu K and Nagai R: Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol. 70:64–73. 2014. View Article : Google Scholar : PubMed/NCBI
2	Weber KT and Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 83:1849–1865. 1991. View Article : Google Scholar : PubMed/NCBI
3	Young MJ and Funder JW: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol. 271:E883–E888. 1996.PubMed/NCBI
4	MacKenna D, Summerour SR and Villarreal FJ: Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res. 46:257–263. 2000. View Article : Google Scholar : PubMed/NCBI
5	Davis J and Molkentin JD: Myofibroblasts: Trust your heart and let fate decide. J Mol Cell Cardiol. 70:9–18. 2014. View Article : Google Scholar : PubMed/NCBI
6	Bader M, Peters J, Baltatu O, Muller DN, Luft FC and Ganten D: Tissue renin-angiotensin systems: New insights from experimental animal models in hypertension research. J Mol Med (Berl). 79:76–102. 2001. View Article : Google Scholar : PubMed/NCBI
7	Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ and Egido J: Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension. 38:1382–1387. 2001. View Article : Google Scholar : PubMed/NCBI
8	Villarreal FJ, Kim NN, Ungab GD, Printz MP and Dillmann WH: Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation. 88:2849–2861. 1993. View Article : Google Scholar : PubMed/NCBI
9	Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K and Iwao H: Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 25:1252–1259. 1995. View Article : Google Scholar : PubMed/NCBI
10	Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE and Hsueh WA: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 101:1130–1137. 2000. View Article : Google Scholar : PubMed/NCBI
11	González A, López B, Querejeta R and Diez J: Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol. 34:1585–1593. 2002. View Article : Google Scholar : PubMed/NCBI
12	Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Mullerova M, Bednarova K, Adamcova M and Paulis L: Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens. (Suppl 27):S5–S10. 2009. View Article : Google Scholar
13	Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, et al: Discovery and characterization of alamandine: A novel component of the renin-angiotensin system. Circ Res. 112:1104–1111. 2013. View Article : Google Scholar : PubMed/NCBI
14	Habiyakare B, Alsaadon H, Mathai ML, Hayes A and Zulli A: Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: Differential effects of alamandine and Ang(1–7). Int J Exp Pathol. 95:290–295. 2014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Soares ER, Barbosa CM, Campagnole-Santos MJ, Santos RAS and Alzamora AC: Hypotensive effect induced by microinjection of Alamandine, a derivative of angiotensin-(1–7), into caudal ventrolateral medulla of 2K1C hypertensive rats. Peptides. 96:67–75. 2017. View Article : Google Scholar : PubMed/NCBI
17	Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, et al: Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol. 27:297–302. 2007. View Article : Google Scholar : PubMed/NCBI
18	Shinohara T, Harada M, Ogi K, Maruyama M, Fujii R, Tanaka H, Fukusumi S, Komatsu H, Hosoya M, Noguchi Y, et al: Identification of a G protein-coupled receptor specifically responsive to beta-alanine. J Biol Chem. 279:23559–23564. 2004. View Article : Google Scholar : PubMed/NCBI
19	Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G, Lukaszuk A, Tourwé D, Chai SY, Albiston AL, et al: Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent. Hypertension. 57:956–964. 2011. View Article : Google Scholar : PubMed/NCBI
20	Coutinho DC, Foureaux G, Rodrigues KD, Salles RL, Moraes PL, Murça TM, De Maria ML, Gomes ER, Santos RA, Guatimosim S and Ferreira AJ: Cardiovascular effects of angiotensin A: A novel peptide of the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst. 15:480–486. 2014. View Article : Google Scholar : PubMed/NCBI
21	Qaradakhi T, Apostolopoulos V and Zulli A: Angiotensin (1–7) and Alamandine: Similarities and differences. Pharmacol Res. 111:820–826. 2016. View Article : Google Scholar : PubMed/NCBI
22	Sun Y, Ramires FJ, Zhou G, Ganjam VK and Weber KT: Fibrous tissue and angiotensin II. J Mol Cell Cardiol. 29:2001–2012. 1997. View Article : Google Scholar : PubMed/NCBI
23	Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I and Díez J: Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 17:107–114. 1999. View Article : Google Scholar : PubMed/NCBI
24	Brown L, Duce B, Miric G and Sernia C: Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol. 10 (Suppl 11):S143–S148. 1999.PubMed/NCBI
25	Crawford DC, Chobanian AV and Brecher P: Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 74:727–739. 1994. View Article : Google Scholar : PubMed/NCBI
26	Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K and Karagiannis A: Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution? Expert Opin Pharmacother. 8:529–535. 2007. View Article : Google Scholar : PubMed/NCBI
27	Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, Bhandari B and Abboud HE: NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkB signaling pathways. Circulation. 131:643–655. 2015. View Article : Google Scholar : PubMed/NCBI
28	Lin CY, Hsu YJ, Hsu SC, Chen Y, Lee HS, Lin SH, Huang SM, Tsai CS and Shih CC: CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia. J Mol Cell Cardiol. 85:249–261. 2015. View Article : Google Scholar : PubMed/NCBI
29	Tian B, Liu J, Bitterman P and Bache RJ: Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. Am J Physiol Heart Circ Physiol. 285:H1105–1112. 2003. View Article : Google Scholar : PubMed/NCBI
30	Arumugam S, Sreedhar R, Thandavarayan RA, Karuppagounder V, Krishnamurthy P, Suzuki K, Nakamura M and Watanabe K: Angiotensin receptor blockers: Focus on cardiac and renal injury. Trends Cardiovasc Med. 26:221–228. 2016. View Article : Google Scholar : PubMed/NCBI
31	Zulli A, Hare DL, Buxton BF and Widdop RE: Vasoactive role for angiotensin II type 2 receptors in human radial artery. Int J Immunopathol Pharmacol. 27:79–85. 2014. View Article : Google Scholar : PubMed/NCBI
32	Dong X, Han S, Zylka MJ, Simon MI and Anderson DJ: A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell. 106:619–632. 2001. View Article : Google Scholar : PubMed/NCBI
33	Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, Hoffert C, Cao J, Schmidt R, Pelletier M, et al: Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci. 5:201–209. 2002. View Article : Google Scholar : PubMed/NCBI
34	Nishimura S, Uno M, Kaneta Y, Fukuchi K, Nishigohri H, Hasegawa J, Komori H, Takeda S, Enomoto K, Nara F and Agatsuma T: MRGD, a MAS-related G-protein coupled receptor, promotes tumorigenisis and is highly expressed in lung cancer. PLoS One. 7:e386182012. View Article : Google Scholar : PubMed/NCBI
35	Council NR: Guide for the care and use of laboratory animals. The National Academies Press; Washington, DC: 1996, PubMed/NCBI
36	Leary S, Underwood W, Anthony R, Cartner S, Corey D, Grandin T, Greenacre C, Gwaltney-Brant S, McCrackin MA, Meyer R, et al: AVMA guidelines for the euthanasia of animals: 2013 Edition. American Veterinary Medical Association. 2013.